SCHEDULE: Vivo Fund Amends Soleno Therapeutics Stake
Beneficial Ownership Disclosure
Vivo Opportunity Fund Holdings, L.P. and its general partner, Vivo Opportunity, LLC, have updated their beneficial ownership in Soleno Therapeutics, Inc. to 7.4%.
Summary
- Vivo Opportunity Fund Holdings, L.P. and Vivo Opportunity, LLC reported beneficial ownership of 3,958,294 shares of Soleno Therapeutics, Inc. Common Stock.
- This represents 7.4% of the outstanding Common Stock.
- The percentage is calculated based on 53,145,009 shares outstanding as of August 1, 2025, as reported in Soleno Therapeutics' Form 10-Q filed on August 6, 2025.
- The reporting persons have sole voting and sole dispositive power over all 3,958,294 shares.
- This filing is an Amendment No. 2 to a Schedule 13G, indicating an update to a previously disclosed passive ownership stake.
Sentiment
Score: 5
Explanation: The filing is a neutral, factual disclosure of beneficial ownership, providing no explicit positive or negative sentiment regarding the company's performance or prospects.
Positives
- Vivo Opportunity Fund Holdings, L.P. and Vivo Opportunity, LLC maintain a significant 7.4% beneficial ownership stake in Soleno Therapeutics, Inc., indicating continued institutional investment.
Risks
- The reporting persons certify that the securities were not acquired or held for the purpose of changing or influencing control of the issuer, indicating a passive investment approach.
Future Outlook
NA
Industry Context
This filing is a routine disclosure of a passive ownership stake by an institutional investor in a biopharmaceutical company. It does not provide specific insights into broader industry trends or competitive dynamics, but rather reflects an investment decision within the sector.
Stakeholder Impact
- This filing primarily impacts shareholders by providing transparency on significant institutional ownership. It does not directly impact employees, customers, suppliers, or creditors.
Key Dates
| Date | Description |
|---|---|
| 06/30/2025 | Date of event which requires filing of this statement |
| 08/01/2025 | Date as of which 53,145,009 shares of Common Stock were outstanding, used for percentage calculation |
| 08/06/2025 | Date Soleno Therapeutics, Inc. filed its Quarterly Report on Form 10-Q with the SEC |
| 08/12/2025 | Date of signing of the Schedule 13G Amendment No. 2 |
Keywords
Soleno Therapeutics, Vivo Opportunity Fund, Vivo Opportunity LLC, Schedule 13G, Beneficial Ownership, Common Stock, Institutional Investor, SEC Filing, Biopharma
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.